Combination SGLT2 inhibitor and GLP-1 receptor agonist therapy: a complementary approach to the treatment of type 2 diabetes
出版年份 2017 全文链接
标题
Combination SGLT2 inhibitor and GLP-1 receptor agonist therapy: a complementary approach to the treatment of type 2 diabetes
作者
关键词
-
出版物
POSTGRADUATE MEDICINE
Volume 129, Issue 7, Pages 686-697
出版商
Informa UK Limited
发表日期
2017-06-28
DOI
10.1080/00325481.2017.1342509
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Rationale and design of the EXenatide Study of Cardiovascular Event Lowering (EXSCEL) trial
- (2016) Rury R. Holman et al. AMERICAN HEART JOURNAL
- Diabetes Medications as Monotherapy or Metformin-Based Combination Therapy for Type 2 Diabetes
- (2016) Nisa M. Maruthur et al. ANNALS OF INTERNAL MEDICINE
- Self-reported Barriers to Adherence and Persistence to Treatment With Injectable Medications for Type 2 Diabetes
- (2016) C. Victor Spain et al. CLINICAL THERAPEUTICS
- Positioning SGLT2 Inhibitors/Incretin-Based Therapies in the Treatment Algorithm
- (2016) John P.H. Wilding et al. DIABETES CARE
- SGLT2 Inhibitors and Cardiovascular Risk: Lessons Learned From the EMPA-REG OUTCOME Study
- (2016) Muhammad Abdul-Ghani et al. DIABETES CARE
- CV Protection in the EMPA-REG OUTCOME Trial: A “Thrifty Substrate” Hypothesis
- (2016) Ele Ferrannini et al. DIABETES CARE
- Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis
- (2016) F. Zaccardi et al. DIABETES OBESITY & METABOLISM
- Dapagliflozin once-daily and exenatide once-weekly dual therapy: A 24-week randomized, placebo-controlled, phase II study examining effects on body weight and prediabetes in obese adults without diabetes
- (2016) Per Lundkvist et al. DIABETES OBESITY & METABOLISM
- CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM –2016 EXECUTIVE SUMMARY
- (2016) Alan J. Garber et al. Endocrine Practice
- AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY POSITION STATEMENT ON THE ASSOCIATION OF SGLT-2 INHIBITORS AND DIABETIC KETOACIDOSIS
- (2016) Yehuda Handelsman et al. Endocrine Practice
- Adherence to antihyperglycemic treatment: a work in progress
- (2016) Konstantinos Tziomalos EXPERT OPINION ON PHARMACOTHERAPY
- Comparison of Clinical Outcomes and Adverse Events Associated With Glucose-Lowering Drugs in Patients With Type 2 Diabetes
- (2016) Suetonia C. Palmer et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- The EMPA-REG study: What has it told us? A diabetologist’s perspective
- (2016) Ralph A. DeFronzo JOURNAL OF DIABETES AND ITS COMPLICATIONS
- EMPA-REG – the “diuretic hypothesis”
- (2016) John McMurray JOURNAL OF DIABETES AND ITS COMPLICATIONS
- Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus
- (2016) Abd A. Tahrani et al. Nature Reviews Endocrinology
- Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
- (2016) Christoph Wanner et al. NEW ENGLAND JOURNAL OF MEDICINE
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and Acceptability of Glycemic Control of Glucagon-Like Peptide-1 Receptor Agonists among Type 2 Diabetes: A Systematic Review and Network Meta-Analysis
- (2016) Zhixia Li et al. PLoS One
- Clinical and Patient-Related Variables Associated with Initiating GLP-1 Receptor Agonist Therapy in Type 2 Diabetes Patients in Primary Care in Germany
- (2016) Qing Qiao et al. PLoS One
- Impact of telephonic interviews on persistence and daily adherence to insulin treatment in insulin-naïve type 2 diabetes patients: dropout study
- (2016) Dilek Gogas Yavuz et al. Patient Preference and Adherence
- SGLT-2 receptor inhibitors for treating patients with type 2 diabetes mellitus: a systematic review and network meta-analysis
- (2016) Deepson S Shyangdan et al. BMJ Open
- GLP-1 receptor agonists and SGLT2 inhibitors: a couple at last?
- (2016) Michael A Nauck et al. Lancet Diabetes & Endocrinology
- Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial
- (2016) Juan P Frías et al. Lancet Diabetes & Endocrinology
- Predictors of Change in Adherence Status from 1 Year to the Next Among Patients with Type 2 Diabetes Mellitus on Oral Antidiabetes Drugs
- (2016) Vishal Saundankar et al. Journal of Managed Care & Specialty Pharmacy
- Adherence to GLP-1 receptor agonist therapy administered by once-daily or once-weekly injection in patients with type 2 diabetes in Germany
- (2016) Karel Kostev et al. Diabetes Metabolic Syndrome and Obesity-Targets and Therapy
- Benefits and Harms of Once-Weekly Glucagon-like Peptide-1 Receptor Agonist Treatments
- (2015) Francesco Zaccardi et al. ANNALS OF INTERNAL MEDICINE
- Effect of Glucagon-like Peptide-1 Receptor Agonists on Lipid Profiles Among Type 2 Diabetes: A Systematic Review and Network Meta-analysis
- (2015) Feng Sun et al. CLINICAL THERAPEUTICS
- β Cell Dysfunction Versus Insulin Resistance in the Pathogenesis of Type 2 Diabetes in East Asians
- (2015) Daisuke Yabe et al. Current Diabetes Reports
- A discrete-choice experiment to quantify patient preferences for frequency of glucagon-like peptide-1 receptor agonist injections in the treatment of type 2 diabetes
- (2015) A. Brett Hauber et al. CURRENT MEDICAL RESEARCH AND OPINION
- Deciphering Metabolic Messages From the Gut Drives Therapeutic Innovation: The 2014 Banting Lecture
- (2015) Daniel J. Drucker DIABETES
- SGLT-2 inhibitors and cardiovascular risk: Proposed pathways and review of ongoing outcome trials
- (2015) Silvio E Inzucchi et al. Diabetes & Vascular Disease Research
- Empagliflozin reduces body weight and indices of adipose distribution in patients with type 2 diabetes mellitus
- (2015) Ian J Neeland et al. Diabetes & Vascular Disease Research
- Energy Balance After Sodium–Glucose Cotransporter 2 Inhibition
- (2015) Giulia Ferrannini et al. DIABETES CARE
- Initial combination therapy with metformin, pioglitazone and exenatide is more effective than sequential add-on therapy in subjects with new-onset diabetes. Results from the Efficacy and Durability of Initial Combination Therapy for Type 2 Diabetes (EDICT
- (2015) M. A. Abdul-Ghani et al. DIABETES OBESITY & METABOLISM
- Efficacy and safety of once-weekly glucagon-like peptide 1 receptor agonists for the management of type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials
- (2015) T. Karagiannis et al. DIABETES OBESITY & METABOLISM
- Efficacy and safety of canagliflozin when used in conjunction with incretin-mimetic therapy in patients with type 2 diabetes
- (2015) G. Fulcher et al. DIABETES OBESITY & METABOLISM
- Effects of three injectable antidiabetic agents on glycaemic control, weight change and drop-out in type 2 diabetes suboptimally controlled with metformin and/or a sulfonylurea: A network meta-analysis
- (2015) Xihua Zhong et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- A Decision Support Tool for Appropriate Glucose-Lowering Therapy in Patients with Type 2 Diabetes
- (2015) F. Javier Ampudia-Blasco et al. Diabetes Technology & Therapeutics
- SGLT-2 INHIBITOR THERAPY ADDED TO GLP-1 AGONIST THERAPY IN THE MANAGEMENT OF T2DM
- (2015) Rachel M. Saroka et al. Endocrine Practice
- AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY – CLINICAL PRACTICE GUIDELINES FOR DEVELOPING A DIABETES MELLITUS COMPREHENSIVE CARE PLAN – 2015
- (2015) Yehuda Handelsman et al. Endocrine Practice
- Efficacy and safety of sodium–glucose cotransporter 2 inhibitors in type 2 diabetes: a meta-analysis of randomized controlled trials for 1 to 2 years
- (2015) Xiang-Yang Liu et al. JOURNAL OF DIABETES AND ITS COMPLICATIONS
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
- (2015) Bernard Zinman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
- (2015) Marc A. Pfeffer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Euglycemic diabetic ketoacidosis induced by SGLT2 inhibitors: possible mechanism and contributing factors
- (2015) Wataru Ogawa et al. Journal of Diabetes Investigation
- Development of a patient decision aid for type 2 diabetes mellitus for patients not achieving glycemic control on metformin alone
- (2015) Alicia Shillington et al. Patient Preference and Adherence
- Effects of Glucagon-Like Peptide-1 Receptor Agonists on Weight Loss in Patients with Type 2 Diabetes: A Systematic Review and Network Meta-Analysis
- (2015) Feng Sun et al. Journal of Diabetes Research
- The Effect of Glucagon-Like Peptide 1 Receptor Agonists on Weight Loss in Type 2 Diabetes: A Systematic Review and Mixed Treatment Comparison Meta-Analysis
- (2015) Jessica E. Potts et al. PLoS One
- Comparative Efficacy and Safety of Antidiabetic Drug Regimens Added to Metformin Monotherapy in Patients with Type 2 Diabetes: A Network Meta-Analysis
- (2015) Elizabeth S. Mearns et al. PLoS One
- Cardiovascular Actions of Incretin-Based Therapies
- (2014) John R. Ussher et al. CIRCULATION RESEARCH
- Cardiovascular Actions of GLP-1 and Incretin-Based Pharmacotherapy
- (2014) Angelo Avogaro et al. Current Diabetes Reports
- Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes
- (2014) Silvio E. Inzucchi et al. DIABETES CARE
- Dapagliflozin: A Review of Its Use in Patients with Type 2 Diabetes
- (2014) Greg L. Plosker DRUGS
- Evaluating SGLT2 inhibitors for type 2 diabetes: pharmacokinetic and toxicological considerations
- (2014) André J Scheen Expert Opinion on Drug Metabolism & Toxicology
- Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production
- (2014) Aurora Merovci et al. JOURNAL OF CLINICAL INVESTIGATION
- Incretin physiology and pathophysiology from an Asian perspective
- (2014) Young Min Cho Journal of Diabetes Investigation
- Impact of hypoglycemia on patients with type 2 diabetes mellitus and their quality of life, work productivity, and medication adherence
- (2014) Janice Lopez et al. Patient Preference and Adherence
- Glucagon-like peptide 1 receptor agonist therapy is more efficacious than insulin glargine for poorly controlled type 2 diabetes: A systematic review and meta-analysis
- (2014) Fu-peng Liu et al. Journal of Diabetes
- Renal effects of dapagliflozin in patients with type 2 diabetes
- (2014) Merlin C. Thomas Therapeutic Advances in Endocrinology and Metabolism
- Sodium–Glucose Cotransporter 2 Inhibitors for Type 2 Diabetes
- (2013) Despoina Vasilakou et al. ANNALS OF INTERNAL MEDICINE
- Pharmacology, Physiology, and Mechanisms of Incretin Hormone Action
- (2013) Jonathan E. Campbell et al. Cell Metabolism
- Efficacy, Safety, and Tolerability of Exenatide Once Weekly in Patients With Type 2 Diabetes Mellitus: An Integrated Analysis of the DURATION Trials
- (2013) Michael Grimm et al. POSTGRADUATE MEDICINE
- From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus
- (2009) R. A. DeFronzo DIABETES
- Exenatide Reduces Infarct Size and Improves Cardiac Function in a Porcine Model of Ischemia and Reperfusion Injury
- (2009) Leo Timmers et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Cardioprotective and Vasodilatory Actions of Glucagon-Like Peptide 1 Receptor Are Mediated Through Both Glucagon-Like Peptide 1 Receptor–Dependent and –Independent Pathways
- (2008) Kiwon Ban et al. CIRCULATION
- Protective effects of GLP-1 analogues exendin-4 and GLP-1(9–36) amide against ischemia–reperfusion injury in rat heart
- (2007) David P. Sonne et al. REGULATORY PEPTIDES
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now